Memantine Canon, tablets 5 mg 30 pcs

A derivative of adamantane, similar in chemical structure and pharmacological properties to amantadine.

Memantine blocks glutamate NMDA receptors (including in the substantia nigra), thus reducing the overstimulating effect of cortical glutamate neurons on the neostratum, which develops against the background of insufficient dopamine release.

There is currently no evidence base reliably demonstrating the drug’s ability to slow or prevent the progressive course of Alzheimer’s disease.

Indications

Dementia (Alzheimer’s type, vascular, mixed dementia of all degrees of severity); CNS disorders of mild to moderate severity (impaired memory and ability to concentrate, loss of interest in activities, rapid fatigue, limited ability to serve oneself); cerebral and spinal spastic syndrome (due to craniocerebral injury, multiple sclerosis, stroke), Parkinson’s disease, Parkinsonism.

Active ingredient

Composition

1 film-coated tablet, 5 mg contains:

the active ingredient:

memantine hydrochloride 5 mg;

excipients:

calcium hydrophosphate dihydrate 24.3 mg,

colloidal silicon dioxide 2 mg,

croscarmellose sodium 2.8 mg,

Lactose monohydrate 61.6 mg,

Magnesium stearate 0.7 mg,

Povidone K-30 3.6 mg;

Film coating:

Opadray white 3 mg, including: hypromellose
(hydroxypropyl methylcellulose) 1.0125 mg, hyprolose (hydroxypropylcellulose) 1.0125 mg, talc 0.6 mg, titanium dioxide 0.375 mg.

How to take, the dosage

Overly, with meals, tablets without chewing and with liquids. Adults with dementia take 5mg per day (7 days), 10mg per day (7 days), and 15 to 20mg per day (7 days).

If necessary, the dose can be gradually increased to 30 mg per day. In movement disorders – 10mg per day (1-7th day), 20mg per day (8-14 days) and 20-30mg per day (15-21 days).

A further increase in dose up to 60mg per day per week is possible. In children at the rate of 0.5mg/kg/day.

Interaction

Simultaneous use with levodopa preparations, dopamine receptor agonists, m-cholinoblockers may increase their effect.

Concomitant use with barbiturates, neuroleptics may decrease their effect.

Concomitant use may change (increase or decrease) the effect of dantrolene or baclofen, so the doses of the drugs should be adjusted individually.

Concomitant use with phenytoin, amantadine, ketamine and dextramethorphan should be avoided.

Possible increase in plasma concentrations of cimetidine, procainamide, quinidine, quinine and nicotine when concomitantly taken with memantine.

Possible decrease in concentrations of hydrochlorthiazide when concomitantly administered with memantine.

In the experience of post-marketing use of the drug, there have been isolated cases of decreased MHO in patients concomitantly taking warfarin.

In pharmacokinetic studies in healthy young volunteers, no interaction effects have been reported with metformin or donepezil when taking memantine on a single occasion.

In similar studies, no interaction was also found with galantamine.

Contraindications

Severe renal failure; severe hepatic failure; congenital galactose intolerance; lactase deficiency or impaired glucose/galactose absorption syndrome; pregnancy, lactation; childhood under 18 years (efficacy and safety not established); hypersensitivity.

With caution, use in patients with thyrotoxicosis, epilepsy, myocardial infarction (including In anamnesis), heart failure III-IV functional class NYHA, convulsive syndrome in anamnesis, in concurrent use of antagonists of NMDA-receptors (amantadine, ketamine, dextromethorphan), in the presence of factors urine pH-raising factors (sudden change of diet, abundant intake of gastric buffers), severe urinary tract infections, uncontrolled arterial hypertension, renal insufficiency, hepatic insufficiency.

Side effects

Dizziness, internal or motor restlessness, increased agitation, fatigue, increased intracranial pressure, nausea.

Overdose

Limited information on overdoses has been available in ongoing clinical studies and postmarketing studies of the drug.

Symptoms: In sufficiently large overdoses (200 mg once or more than 100 mg daily for 3 days) the following symptoms have been identified: weakness, fatigue, diarrhea, or no symptoms. In overdose less than 140 mg or in unknown overdose, the following adverse events have been identified on the nervous system (confusion, drowsiness, dizziness, agitation, aggression, hallucinations, and gait disturbance) and on the gastrointestinal tract (vomiting and diarrhea).

In the most serious cases of overdose, the patient survived after taking more than 2000 mg of memantine with adverse events from the nervous system (coma for 10 days, diplopia, agitation). The patient received symptomatic therapy and plasmapheresis and recovered without any sequelae.

The other case of a serious overdose described was 400 mg once. The patient recovered without consequences. Nervous system reactions were noted: anxiety, psychosis, visual hallucinations, stupor, drowsiness, unconsciousness.

Treatment:In case of overdose, symptomatic treatment should be carried out. There is no specific antidote for memantine intoxication. Carry out standard procedures to evacuate the drug by lavage, the use of activated charcoal, forced diuresis, means to alkalize the urine. If symptoms of central nervous system overexcitation occur, symptomatic therapy should be chosen extremely carefully.

Similarities